alogliptin (Nesina)
Jump to navigation
Jump to search
Indications
Contraindications
- does not decrease risk of cardiovascular events after acute coronary syndrome[2]
Dosage
tablet
Adverse effects
- rhinorrhea
- upper respiratory tract infection
- headache
- risk for hypoglycemia is low
- may increase risk of may increase the risk of heart failure, particularly in patients with heart disease or kidney disease[3][4]
Mechanism of action
- gliptin
- lowers hemoglobin A1c 0.3% compared with placebo[2]
More general terms
Component of
References
- ↑ 1.0 1.1 FDA News Release: Jan. 25, 2013 FDA approves three new drug treatments for type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm
- ↑ 2.0 2.1 2.2 White WB et al. for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 Sep 2 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23992602 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1305889
- ↑ 3.0 3.1 Zannad F et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet 2015 Mar 9; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25765696 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2962225-X/abstract
Standl E and Schnell O. DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 2015 Mar 9 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25765695 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960037-X/abstract - ↑ 4.0 4.1 FDA Safety Alert. April 5, 2015 Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm